EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of SARS-CoV-2 Pandemic on Diagnosis of Prostate Cancer

Immanuel A Oppolzer, Marco J Schnabel, Selma Hammer, Hannah Zilles, Maximilian Haas, Christopher Goßler, Maximilian R Müller, Maximilian Burger, Michael Gierth

Urologia Internationalis · 2024

DOI: 10.1159/000541753 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Urologia Internationalis, 2024. Verfasst von Immanuel A Oppolzer und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany. Hauptthemen laut MEDLINE: COVID-19, Prostatic Neoplasms, Delayed Diagnosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aim of this study was to prove if the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic resulted in a delay in diagnosis and treatment of prostate cancer (PC).

Methods

A monocentric, retrospective analysis was conducted at a university cancer center. Included were all patients with untreated PC diagnosed between January 2019 and December 2021. The observation covered 22 months of the SARS-CoV-2 pandemic and 14 months preceding it.

Results

Nine hundred sixty-nine men prior (T0) and 1,343 during the pandemic (T1) were included. Mean age was 68.0 (SD 8.2). Median initial prostate-specific antigen was 8.1 ng/mL (T0) and 7.9 ng/mL (T1, p = 0.288). Time from biopsy to tumor board (T0: 1.3 months vs. T1: 0.9 months, p = 0.001), to staging (T0: 1.1 months vs. T1: 0.75 months, p = 0.707), and to therapy (T0: 3.0 months vs. T1: 2.0 months, p < 0.001) was shortened during the pandemic. Classified by d’Amico, a significant shift toward higher risk groups was seen (p = 0.024). Local staging showed an insignificant increase in locally advanced PCs. Metastatic diseases decreased from 10.3% to 8.9% (p = 0.433). Pathological staging showed pT3+ in 44.4% versus 44.7% (p = 0.565) and pN+ in 9.9% versus 9.6% (p = 0.899).

Conclusion

Regarding the diagnosis and treatment of PC, we could not demonstrate any delays due to the SARS-CoV-2 pandemic.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Prostatic NeoplasmsDelayed DiagnosisHumansMaleRetrospective StudiesAgedMiddle AgedNeoplasm StagingSARS-CoV-2PandemicsTime FactorsAged, 80 and over

Stichwörter der Autor:innen

COVID-19Clinical dataDelay in diagnosisProstate cancerSevere acute respiratory syndrome coronavirus 2

Autor:innen und Institutionen

  • Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.

Zitieren

APA

Oppolzer, I. A., Schnabel, M. J., Hammer, S., Zilles, H., Haas, M., Goßler, C., Müller, M. R., Burger, M., & Gierth, M. (2024). Impact of SARS-CoV-2 Pandemic on Diagnosis of Prostate Cancer. Urologia Internationalis. https://doi.org/10.1159/000541753

Vancouver

Oppolzer IA, Schnabel MJ, Hammer S, Zilles H, Haas M, Goßler C, et al. Impact of SARS-CoV-2 Pandemic on Diagnosis of Prostate Cancer. Urologia Internationalis. 2024. doi:10.1159/000541753

BibTeX
@article{Oppolzer2024,
  author = {Oppolzer, Immanuel A and Schnabel, Marco J and Hammer, Selma and Zilles, Hannah and Haas, Maximilian and Goßler, Christopher and Müller, Maximilian R and Burger, Maximilian and Gierth, Michael},
  title = {Impact of SARS-CoV-2 Pandemic on Diagnosis of Prostate Cancer},
  journal = {Urologia Internationalis},
  year = {2024},
  doi = {10.1159/000541753}
}
Kostenlos starten →